Total: $929.541M | ||||
Company |
Type Of |
Number Of Shares, Units Or Warrants (M) |
Amount |
Investors; Placement |
| | ||||
Alkermes Inc. |
Private |
N/A |
$100 |
Alkermes priced $100M worth of the |
|
|
|||
AtheroGenics |
Private |
N/A |
$100 |
AtheroGenics raised $100M through a |
|
|
|||
Australian |
Private |
N/A |
A$2.4 |
Australian Cancer Technology raised |
|
|
|||
Bio-Rad |
Private |
N/A |
$225 |
Bio-Rad agreed to sell $225M worth of |
BioSante Pharmaceuticals Inc. (OTC BB:BISP) |
Private placement of common stock |
4.8S |
$10.3 |
BioSante raised $10.3M in the placement led by SDS Merchant Fund; other investors were Perceptive Life Sciences Fund, SCO Capital Partners LLC, Quogue Capital LLC, Crestview Capital and Orion Biomedical Funds; four BioSante directors also participated (8/6) |
|
|
|||
Cepheid Inc. |
Private |
2.8S |
$10 |
Cepheid raised about $10M after selling about 2.8M common shares to an unnamed institutional investor; UBS Securities LLC acted as the offering's financial adviser (8/14) |
|
|
|||
Ciphergen |
Private |
N/A |
$30 |
Ciphergen raised $30M in a convertible notes offering (8/19) |
|
|
|||
Cortex |
Private placement of common stock and warrants |
3.3S and |
$5 |
Cortex raised $5M in a private placement with institutional investors; Rodman & Renshaw Inc. served as placement agent for the transaction (8/22) |
|
|
|||
Curis |
Private placement of common stock and warrants |
3.6S and W for 1.1S |
$10.9 |
Curis raised about $10.9M through the financing; Stephens Inc. was the transaction's placement agent (8/11) |
EpiTan Ltd. (Australia; ASX:EPT) |
Private placement of common stock |
14.5S |
A$7.4( |
EpiTan raised US$4.8M through a placement of 14.5M shares (8/25) |
|
|
|||
Genelabs Technologies Inc. (GNLB) |
Private placement of common stock |
1.7S |
$2.7 |
Genelabs raised $2.7M by placing 1.7M shares with one institutional investor; SG Cowen acted as placement agent (8/4) |
Genetic Technologies (Australia; ASX:GTG) |
Private placement of common stock |
13.3S |
A$10 (US$6.5) |
Genetic Technologies raised US$6.5M through a placement of about 13.3M shares; the placement was managed by Emerging Growth Capital (8/25) |
|
|
|||
GlycoGenesys Inc. (GLGS) |
Private placement of common stock and warrants |
7.5S and |
$4 |
GlycoGenesys raised about $4M in proceeds from institutional and accredited investors (8/22) |
|
|
|||
Invitrogen Corp. (IVGN) |
Private placement of convertible notes |
N/A |
$25 |
Invitrogen raised an additional $25M as part of its $325M convertible notes offering announced in July (8/14) |
|
|
|||
Labopharm Inc. (Canada; TSE:DDS) |
Private placement of common stock |
0.2348 |
C$1.15 (US$0.827) |
Labopharm raised another US$827,000 after issuing 234,800 common shares at C$4.90 apiece in an overallotment option exercised by underwriters from its previously reported bought-deal financing conducted in June (8/18) |
|
|
|||
LifeCell Corp. |
Private placement of common stock |
3.3S |
$14 |
LifeCell raised $14M placing about 3.3M shares at $4.25 each; Wells Fargo Securities LLC and Roth Capital Partners LLC were the transaction's placement agents (8/11) |
Magistral Biotech |
Private placement of units |
U for 3.6S and 0.36W |
C$0.724 (US$0.514) |
Magistral raised US$514,000 after issuing about 3.6M units composed of about 3.6M common shares and about 360,000 warrants to acquire about 360,000 common shares (8/21) |
|
|
|||
Nymox Pharmaceutical |
Private placement of common stock |
N/A |
$12 |
Nymox raised $12M through the sale of common stock to institutional investors (8/27) |
|
|
|||
Oncolytics Biotech Inc. (Canada; ONCY; TSE:ONC) |
Private placement of common stock and warrants |
1.36S and 0.682W |
C$4.1 (US$2.9) |
Oncolytics raised US$2.9M through a private sale of about 1.36M shares and 682,000 common share purchase warrants to a group of European and Canadian investors (8/18) |
|
|
|||
Penwest Pharmaceuticals Co. (PPCO) |
Private placement of common stock |
2.5S |
$52.7 |
Penwest raised $52.7M, selling a total of 2.5M shares over two days (8/4) |
|
|
|||
Prima Biomed Ltd. (Australia; ASX:PRR) |
Private placement of common stock |
11.6S |
A$4.3 (US$2.8) |
Prima Biomed raised about US$2.8M through the sale of about 11.6M common shares to investment clients of Peregrine Corp. Ltd. (8/8) |
|
|
|||
QLT Inc. (QLTI) |
Private placement of convertible senior notes |
N/A |
$172.5 |
QLT raised $172.5M in the private offering (8/11) |
Serologicals |
Private placement of convertible senior subordinated debentures |
N/A |
$130 |
Serologicals priced the offering of $130M aggregate principal amount of its 4.75% convertible senior subordinated debentures due 2033 (8/15) |
|
|
|||
SIGA Technologies Inc. (SIGA) |
Private placement of common stock and warrants |
0.694S and |
$1 |
SIGA raised $1M from MacAndrews & Forbes Holdings Inc., which received about 694,444 shares and warrants to purchase an additional 347,222 shares (8/14) |
|
|
|||
Tepnel Life Sciences plc (UK; LSE:TED) |
Private placement of common stock |
9.7S |
£1.5 (US$2.4) |
Tepnel raised US$2.4M in a placement with existing and new investors (8/13**) |
|
|
|||
Transgenomic Inc. (TBIO) |
Private placement of common stock |
N/A |
$4.5 |
Transgenomic raised $4.5M in a financing with two of its largest investors; Fahnestock & Co. Inc. served as placement agent (8/28) |
|
|
|||
|
| ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
N/A = Not available, applicable or reported. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | ||||
